Kiniksa Pharmaceuticals International, plc
NASDAQ: KNSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Sanj K. Patel
- Employees
- 366
- Headquarters
- London, United Kingdom
- IPO year
- 2018
- Market cap
- $4.7B
- Website
- https://www.kiniksa.com
Loading KNSA…
Loading profile data…Frequently asked questions about KNSA
What does Kiniksa Pharmaceuticals International, plc (KNSA) do?
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular dis...
Where does KNSA trade?
Kiniksa Pharmaceuticals International, plc (KNSA) trades on the NASDAQ.
What sector is KNSA in?
Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Kiniksa Pharmaceuticals International, plc?
Sanj K. Patel is the chief executive officer of Kiniksa Pharmaceuticals International, plc (KNSA).
Where is Kiniksa Pharmaceuticals International, plc headquartered?
Kiniksa Pharmaceuticals International, plc is headquartered in United Kingdom.
Does KNSA pay a dividend?
Kiniksa Pharmaceuticals International, plc (KNSA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KNSA go public?
Kiniksa Pharmaceuticals International, plc (KNSA) completed its initial public offering in 2018.